PAINWeek 2012

An orally inhaled dihydroergotamine studied for the rescue treatment of acute migraine exhibited significant pain relief compared with placebo, according to the results of a pivotal phase 3 trial presented at PAINWeek 2012

An analysis of tapentadol immediate-release showed it may offer an effective pain management option for post-operative hospitalized patients, as reported at PAINWeek 2012.

Deborah A. Ward, PharmD, from St. Jude Children’s Research Hospital, led a symposium on the different adjuvant therapies in pain management at PAINWeek 2012.

Only a handful of agents are approved for treating CNS pain and there is little hard data to help diagnosis and treatment, Charles E. Argoff, MD, of the Comprehensive Pain Center at Albany (NY) Medical Center, told attendees of PAINWeek 2012.

Tapentadol therapy has nominal effects on luteinizing hormone and testosterone, in contrast to the opioid-induced androgen deficiency observed with other mu-opioid analgesics, according to study results presented at PAINWeek 2012.

Patients with chronic neuropathic pain can be safely and effectively converted and maintained on hydromorphone extended-release, as shown in a study presented at PAINWeek 2012.

Low levels of vitamin D are related to chronic knee pain, according to a study presented at PAINWeek 2012.

Charles E. Argoff, MD, from Albany (NY) Medical Center, discussed diabetic peripheral neuropathy, at PAINWeek 2012, including how to recognize and treat this often undiagnosed condition.

Fentanyl buccal tablets have been shown to provide a more rapid onset of analgesia than immediate-release oxycodone for the relief of breakthrough back pain, as reported at PAINWeek 2012.

As a first-line option, buprenorphine/naloxone can plausibly be given for opioid dependency through a primary care setting, according to a study presented at PAINWeek 2012.